Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 3/20 | 0.54 |
| ▸ | GABRP | O00591 | 7/20 | 0.53 |
| ▸ | GABRD | O14764 | 7/20 | 0.53 |
| ▸ | GABRA1 | P14867 | 7/20 | 0.53 |
| ▸ | GABRB1 | P18505 | 7/20 | 0.53 |
| ▸ | GABRG2 | P18507 | 7/20 | 0.53 |
| ▸ | GABRB3 | P28472 | 7/20 | 0.53 |
| ▸ | GABRA5 | P31644 | 7/20 | 0.53 |
| ▸ | GABRA3 | P34903 | 7/20 | 0.53 |
| ▸ | GABRA2 | P47869 | 7/20 | 0.53 |
| ▸ | GABRB2 | P47870 | 7/20 | 0.53 |
| ▸ | GABRA4 | P48169 | 7/20 | 0.53 |
| ▸ | GABRE | P78334 | 7/20 | 0.53 |
| ▸ | GABRA6 | Q16445 | 7/20 | 0.53 |
| ▸ | GABRG1 | Q8N1C3 | 7/20 | 0.53 |
| ▸ | GABRG3 | Q99928 | 7/20 | 0.53 |
| ▸ | GABRQ | Q9UN88 | 7/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30615643 | 0.82 | GABRP (0.48) | DAOGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL23119573 | 0.79 | CDK5 (0.59) | DAOGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL18425727 | 0.79 | TNKS (0.51) | DAOGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL11356818 | 0.78 | DAO (0.60) | DAOGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL16657373 | 0.78 | TNKS (0.52) | DAOGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL4652549 | 0.77 | CYP19A1 (0.42) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL21464280 | 0.76 | HRH3 (0.48) | DAOGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL3010228 | 0.76 | MAPT (0.50) | DAOGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL21463894 | 0.74 | DAO (0.49) | DAOGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL30615461 | 0.74 | DAO (0.49) | DAOGABRPGABRDGABRA1GABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9845321-B2 | 1,3-dihydro-2H-benzimidazol-2-one derivatives substituted with heterocycles as respiratory syncytial virus antiviral agents | JANSSEN SCIENCES IRELAND UC (IE) | 2017-12-19 | — | — | US | disclosed |
| US-9845321-B2 | 1,3-dihydro-2H-benzimidazol-2-one derivatives substituted with heterocycles as respiratory syncytial virus antiviral agents | JANSSEN SCIENCES IRELAND UC (IE) | 2017-12-19 | — | — | US | disclosed |
| US-20160122346-A1 | NOVEL 1,3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES SUBSTITUTED WITH HETEROCYCLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2016-05-05 | — | — | US | disclosed |
| US-20160122346-A1 | NOVEL 1,3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES SUBSTITUTED WITH HETEROCYCLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2016-05-05 | — | — | US | disclosed |
| US-20150111868-A1 | NOVEL 1,3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES SUBSTITUTED WITH HETEROCYCLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSEN R&D IRELAND (US) | 2015-04-23 | — | — | US | disclosed |
| US-20150111868-A1 | NOVEL 1,3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES SUBSTITUTED WITH HETEROCYCLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSEN R&D IRELAND (US) | 2015-04-23 | — | — | US | disclosed |
| CN-104540817-A | 1,3-dihydro-2H-benzimidazol- 2-one derivatives substituted with heterocycles as respiratory syncytial virus antiviral agents | JANSSEN R & D IRELAND | 2015-04-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122346-A1 | NOVEL 1,3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES SUBSTITUTED WITH HETEROCYCLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | ZC3HAV1, ZC3HAV1L, HELZ | DAO 2045/4885GABRP 2570/4885GABRD 2465/4885 |
| US-20150111868-A1 | NOVEL 1,3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES SUBSTITUTED WITH HETEROCYCLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | ZC3HAV1, ZC3HAV1L, HELZ | DAO 2045/4885GABRP 2570/4885GABRD 2465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.